Clinical Trial Update: Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A) [Phase 1, Phase 2]

View source ↗

Summary

This document announces a Phase 1/2 clinical trial evaluating Opevesostat (MK-5684) alone or in combination for metastatic castration-resistant prostate cancer,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Opevesostat (MK-5684)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Prostatic Neoplasms, Castration-Resistant | Phase 1, Phase 2 | Status: RECRUITING